Watson Announces New Name -- Actavis -- for Global Operations

- Implementing Name Change in 2013 - 
- Redesigned Logo Captures Power of Global Combination - 
- Global Registration of Actavis in Place - 
PARSIPPANY, N.J., Oct. 31, 2012 /CNW/ - Watson Pharmaceuticals, Inc. (NYSE: 
WPI) today announced that it will adopt a new global name – Actavis – 
effective in 2013. The Company said it will initiate a multi-year rebranding 
campaign for its facilities, operations and commercial presence, and will 
transition to trading under a new symbol on the New York Stock Exchange in 
2013. 
"When we announced the proposed acquisition of Actavis in April 2012, we 
immediately instituted an extensive and accelerated review of our global brand 
position and naming equities," said Paul Bisaro, President and CEO of Watson. 
"A pioneer at the dawn of the U.S. generic industry in 1984, the Watson 
corporate name was never registered globally. As we initiated our global 
expansion strategy in 2009, it became clear that we could not establish a 
single, unified market presence under the Watson brand." 
"With our expansion into more than 60 commercial markets around the world, we 
recognized the many benefits of uniting our Company under one name to all 
stakeholders – customers, consumers, payers, institutions and shareholders 
and potential shareholders.  We initiated an extensive review of the name 
equities within our portfolio, as well as assessing the potential of more than 
2,000 potential new names.  As this process progressed, it became clear that 
one of the many assets within the Actavis acquisition was a single name, 
trademarked and protected around the world.  It evokes powerful words: action, 
vision and strength, time-honored attributes of both Watson and Actavis.  
Adopting the Actavis name on a global basis, for our generics, brands and 
biosimilars businesses, was a logical and cost-effective solution." 
Watson has also implemented a distinctive redesign of the Actavis name, which 
reflects the history of both Watson and Actavis.  The new icon in the logo, 
designed by the leading global identity firm Lippincott, speaks to the 
Company's fast-evolving business, as well as its dynamic culture.  A close 
look reveals a "W" shape emerging from a shaded "A," a subtle historical 
reference to the Watson heritage and acquisition of Actavis. 
The color stands out in the universe of pharmaceutical industry competitors 
and reflects growth — a fundamental foundation for the Company and its 
future — and a commitment to be an environmentally responsible company.  The 
result is a new, powerful and accessible visualization that celebrates the 
Company's emergence as a global pharmaceutical leader, and visually defines 
its focus on growth and success in the future. 
Watson intends to officially roll-out this identity in 2013.  Until that time, 
the Company will continue to trade on the New York Stock Exchange under its 
present symbol – WPI. 
Additional resources are available at 
www.multivu.com/mnr/58370-watson-pharmaceuticals-acquires-actavis-group. 
About Watson Pharmaceuticals, Inc. 
Watson Pharmaceuticals, Inc. (NYSE: WPI) is a global, integrated specialty 
pharmaceutical company focused on developing, manufacturing and distributing 
generic, brand and biosimilar products.  The Company has global and U.S. 
headquarters in Parsippany, New Jersey, USA, and international headquarters in 
Zug, Switzerland. 
Watson is the world's third-largest generics manufacturer, with more than 750 
products marketed globally through operations in more than 60 countries.  
Watson's global branded pharmaceutical business develops and markets products 
principally in Urology and Women's Health, and is committed to developing and 
marketing biosimilars products in Women's Health, Oncology and other 
therapeutic categories.  In addition, Watson is the fourth-largest U.S. 
generic pharmaceutical product distributor through its Anda, Inc. business, 
and also develops and out-licenses generic pharmaceutical products outside of 
the U.S. through its Medis third-party business. Watson has announced that it 
will adopt a new global name – Actavis – effective in 2013. 
About LIPPINCOTT 
Lippincott is a leading brand strategy and design firm with a 70-year heritage 
crafting authentic stories, memorable experiences and winning strategies for 
the world's most iconic brands.  Its expertise spans all aspects of brand 
building including strategy, identity design, environmental branding, customer 
experience management and brand activation.  The firm uniquely combines 
business-based strategic thinking and creative excellence to solve complex 
challenges facing corporations today as they shape their brands for the 
future. Recent clients include 3M, Delta Air Lines, Hyatt, Infiniti, Samsung, 
Starbucks and Walmart. Lippincott is part of Oliver Wyman, a global 
professional services organization owned by Marsh & McLennan Companies. 
Forward-Looking Statement 
Statements contained in this press release that refer to Watson's estimated or 
anticipated future results or other non-historical facts are forward-looking 
statements that reflect Watson's current perspective of existing trends and 
information as of the date of this release. For instance, any statements in 
this press release concerning prospects related to Watson's strategic 
initiatives, product introductions and anticipated financial performance are 
forward-looking statements. It is important to note that Watson's goals and 
expectations are not predictions of actual performance. Watson's performance, 
at times, will differ from its goals and expectations. Actual results may 
differ materially from Watson's current expectations depending upon a number 
of factors affecting Watson's business. These factors include, among others, 
the inherent uncertainty associated with financial projections; successful 
integration of the Actavis acquisition and the ability to recognize the 
anticipated synergies and benefits of the Actavis acquisition; the difficulty 
of predicting the timing and outcome of pending or future litigation and 
government investigations and risks that an adverse outcome in such litigation 
or investigations could render Watson liable for substantial damages or 
penalties; risks that resolution of patent infringement litigation through 
settlement could result in investigations or actions by private parties or 
government authorities or agencies; the impact of competitive products and 
pricing; risks related to fluctuations in foreign currency exchange rates; 
periodic dependence on a small number of products for a material source of net 
revenue or income; variability of trade buying patterns; changes in generally 
accepted accounting principles; risks that the carrying values of assets may 
be negatively impacted by future events and circumstances; the timing and 
success of product launches; the difficulty of predicting the timing or 
outcome of product development efforts and regulatory agency approvals or 
actions, if any; risks and uncertainties normally incident to the 
pharmaceutical industry, including product liability claims and the 
availability of product liability insurance on reasonable terms; market 
acceptance of and continued demand for Watson's products; difficulties or 
delays in manufacturing; the availability and pricing of third party sourced 
products and materials; successful compliance with governmental regulations 
applicable to Watson's facilities, products and/or businesses; changes in the 
laws and regulations, including Medicare, Medicaid, and similar laws in 
foreign countries affecting, among other things, pricing and reimbursement of 
pharmaceutical products and the settlement of patent litigation; and such 
other risks and uncertainties detailed in Watson's periodic public filings 
with the Securities and Exchange Commission, including but not limited to 
Watson's Annual Report on Form 10-K for the year ended December 31, 2011 and 
Watson's Quarterly Report on Form 10-Q for the period June 30, 2012. Except as 
expressly required by law, Watson disclaims any intent or obligation to update 
these forward-looking statements. 
 ________________________________
|CONTACTS:|Investors:            |
|_________|______________________|
|         |Lisa DeFrancesco      |
|_________|______________________|
|         |Office: (862) 261-7152|
|_________|______________________|
|         |Mobile: (862) 222-5076|
|_________|______________________|
|         |                      |
|_________|______________________|
|         |Media:                |
|_________|______________________|
|         |Charlie Mayr          |
|_________|______________________|
|         |Office: (862) 261-8030|
|_________|______________________|
|         |Mobile: (862) 222-3528|
|_________|______________________| 
(Logo:  http://photos.prnewswire.com/prnh/20121031/NY03382LOGO ) 
http://www.watson.com 
http://photos.prnewswire.com/prnh/20121031/NY03382LOGO 
PRN Photo Desk, photodesk@prnewswire.com 
SOURCE: Watson Pharmaceuticals, Inc. 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/October2012/31/c3863.html 
CO: Watson Pharmaceuticals, Inc.
ST: New Jersey
NI: MTC HEA  
-0- Oct/31/2012 23:36 GMT